Genetic correlations of brain lesion distribution in multiple sclerosis: An exploratory study

American Journal of Neuroradiology

Volumn 32, Issue 4, 2011, Pages 695-703

  Sombekke, Madeleine H ^a   Vellinga, M M ^a   Uitdehaag, B M J ^a   Barkhof, F ^a   Polman, C H ^a   Arteta, D ^b   Tejedor, D ^b   Martinez, A ^b   Crusius, J B A ^a   Pena A S ^a   Geurts, J J G ^a   Vrenken, H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Progenika Biopharma SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; ARTICLE; BRAIN DAMAGE; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA MICROARRAY; EXPLORATORY RESEARCH; FEMALE; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HUMAN; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; RS2227139; SINGLE NUCLEOTIDE POLYMORPHISM; SPATIAL ORIENTATION; WHITE MATTER;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FRONTAL LOBE; GENE EXPRESSION PROFILING; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79954483559     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2352     Document Type: Article

References (46)

1. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-17 (Pubitemid 30390191)
2. Hooper-van Veen T, Berkhof J, Polman CH, et al. Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis. Immunogenetics 2006;58:347-54. Epub 2006 Apr 13 (Pubitemid 43830098)
3. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385-91 (Pubitemid 27114050)
4. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120(pt 11):2059-69 (Pubitemid 27493740)
5. van Walderveen MA, Barkhof F, Tas MW, et al. Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study. Eur Neurol 1998;40:91-98 (Pubitemid 28369612)
6. Di Perri C, Battaglini M, Stromillo ML, et al. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. Arch Neurol 2008;65:236-43 (Pubitemid 351240787)
7. Vellinga MM, Geurts JJ, Rostrup E, et al. Clinical correlations of brain lesion distribution in multiple sclerosis. J Magn Reson Imaging 2009;29:768-73
8. Lee MA, Smith S, Palace J, et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain 1999;122(pt 7):1261-70
9. Koziol JA, Wagner S, Sobel DF, et al. Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. J Clin Neurosci 2005;12:895-901 (Pubitemid 41744074)
10. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004;3:104-10 (Pubitemid 38121313)
11. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-62 (Pubitemid 47347319)
12. Sawcer S, Ban M, Maranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77:454-67 (Pubitemid 41192651)
13. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;15;18:767-78. Epub 2008 Nov 14
14. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002;125:150-58 (Pubitemid 34084044)
15. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007;104:20896-901. Epub 2007 Dec 17.
16. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1* 0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008;83:219-27
17. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123:144-59 (Pubitemid 34195616)
18. van Veen T, van Winsen L, Crusius JB, et al. [Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype. Neurology 2003;61:1245-49 (Pubitemid 37377545)
19. Deen S, Bacchetti P, High A, et al. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry 2008;79:1190-93
20. Mowry EM, Deen S, Malikova I, et al. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009;80:400-03
21. Butterfield RJ, Blankenhorn EP, Roper RJ, et al. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol 2000;157:637-45 (Pubitemid 30626922)
22. Sombekke MH, Lukas C, Crusius JB, et al. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009;66:1531-36
23. Sepulcre J, Masdeu JC, Palacios R, et al. HLA-DR2 and white matter lesion distribution in MS. J Neuroimaging 2008;18:328-31
24. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31 (Pubitemid 13158528)
25. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-27
26. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-46
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52 (Pubitemid 14237132)
28. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006;38:1166-72 (Pubitemid 44470362)
29. Godde R, Rohde K, Becker C, et al. Association of the HLA region with multiple sclerosis as confirmed by a genome screen using >10,000 SNPs on DNA chips. J Mol Med 2005;83:486-94 (Pubitemid 40922171)
30. Tejedor D, Castillo S, Mozas P, et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005;51:1137-44 (Pubitemid 43079390)
31. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in Multiple Sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin echo images. Neurology 1995;45:1684-90.
32. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143-55 (Pubitemid 35253488)
33. Mazziotta JC, Toga AW, Evans A, et al. A probabilistic atlas of the human brain: theory and rationale for its development - The International Consortium for Brain Mapping (ICBM). Neuroimage 1995;2:89-101
34. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;2(suppl 1):S208-19
35. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1-25 (Pubitemid 34020610)
36. Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008;4:e1000024
37. Zivadinov R, Uxa L, Zacchi T, et al. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 2003;250:1099-106 (Pubitemid 37152560)
38. Zivadinov R, Uxa L, Bratina A, et al. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol 2007;79:521-35
39. Healy BC, Liguori M, Tran D, et al. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010;75:634-40
40. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72:710-16 (Pubitemid 36255969)
41. Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37:1108-12 (Pubitemid 41486664)
42. Wattjes MP, Lutterbey GG, Harzheim M, et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 2006;16:2067-73 (Pubitemid 44193191)
43. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841-51
44. Witte ME, Bo L, Rodenburg RJ, et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol. 2009;219:193-204
45. van Veen T, Nielsen J, Berkhof J, et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2007;190:157-64 (Pubitemid 47625612)
46. Baranzini SE, Galwey NW, Wang J, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 2009;18:2078-90